Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer

Cancer Letters

Volumn 192, Issue 2, 2003, Pages 161-169

  Fujita, Takuji ^a   Miyamoto, Shingo ^a   Onoyama, Ichiro ^a   Sonoda, Kenzo ^a   Mekada, Eisuke ^b   Nakano, Hitoo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Interleukin 8; Lysophosphatidic acid receptors; Reverse transcription polymerase chain reaction; Vascular endothelial growth factor

Indexed keywords

LYSOPHOSPHATIDIC ACID; RECEPTOR; VASCULOTROPIN;

ARTICLE; CARCINOGENESIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 0037474724     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00713-9     Document Type: Article

References (44)

1. Moolenaar W.H., Kranenburg O., Postma F., Zondag G.C. Lysophosphatidic acid: G-protein signalling and cellular responses. Curr. Opin. Cell Biol. 9:1997;168-173.
2. Fang X., Gaudette D., Furui T., Mao M., Estrella V., Eder A., Pustilnik T., Sasagawa T., LaPushin R., Yu S., Jaffe R.B., Wiener J.R., Erickson J.R., Mills G.B. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann. N. Y. Acad. Sci. 905:2000;188-208.
3. Goetzl E.J., Lee H., Dolezalova H., Kalli K.R., Conover C.A., Hu Y.-L., Azuma T., Stossel T.P., Karliner J.S., Jaffe R.B. Mechanisms of lysolipid phosphate effects on cellular survival and proliferation. Ann. N. Y. Acad. Sci. 905:2000;177-187.
4. Fukushima N., Ishii I., Contos J.J.A., Weiner J.A., Chun J. Lysophospholipid receptors. Annu. Rev. Pharmacol. Toxicol. 41:2001;507-534.
5. Xu Y., Gaudette D.C., Boynton J.D., Frankel A., Fang X.-J., Sharma A., Hurteau J., Casey G., Goodbody A., Mellors A., Holub B.J., Mills G.B. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin. Cancer Res. 1:1995;1223-1232.
6. Xu Y., Shen Z., Wiper D.W., Wu M., Morton R.E., Elson P., Kennedy A.W., Belinson J., Markman M., Casey G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. J. Am. Med. Assoc. 280:1998;719-723.
7. Hong G., Baudhuin L.M., Xu Y. Sphingosine-1-phosphate modulates growth and adhesion of ovarian cancer cells. FEBS Lett. 460:1999;513-518.
8. Schwartz B.M., Hong G., Morrison B.H., Wu W., Baudhuin L.M., Xiao Y.-J., Mok S.C., Xu Y. Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. Gynecol. Oncol. 81:2001;291-300.
9. Frankel A., Mills G.B. Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells. Clin. Cancer Res. 2:1996;1307-1313.
10. i-protein-mediated activation of mitogen-activated protein kinase. Biochem. J. 352:2000;135-143.
11. Pustilnik T.B., Estrella V., Wiener J.R., Mao M., Eder A., Watt M.-A.V., Bast R.C. Jr, Mills G.B. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin. Cancer Res. 5:1999;3704-3710.
12. Hu Y.-L., Tee M.-K., Goetzl E.J., Auersperg N., Mills G.B., Ferrara N., Jaffe R.B. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl. Cancer Inst. 93:2001;762-768.
13. Allard J., Barron S., Diaz J., Lubetzki C., Zalc B., Schwartz J.-C., Sokoloff P. A rat G protein-coupled receptor selectively expressed in myelin-forming cells. Eur. J. Neurosci. 10:1998;1045-1053.
14. A1/edg-2 is expressed by mature oligodendrocytes during myelination in the postnatal murine brain. J. Comp. Neurol. 398:1998;587-598.
15. An S., Bleu T., Hallmark O.G., Goetzl E.J. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J. Biol. Chem. 273:1998;7906-7910.
16. Bandoh K., Aoki J., Hosono H., Kobayashi S., Kobayashi T., Murakami-Murofushi K., Tsujimoto M., Arai H., Inoue K. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J. Biol. Chem. 274:1999;27776-27785.
17. Im D.-S., Heise C.E., Harding M.A., George S.R., O'Dowd B.F., Theodorescu D., Lynch K.R. Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg7, expressed in prostate. Mol. Pharmacol. 57:2000;753-759.
18. Goetzl E.J., Dolezalova H., Kong Y., Hu Y.-L., Jaffe R.B., Kalli K.R., Conover C.A. Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res. 59:1999;5370-5375.
19. Furui T., LaPushin R., Mao M., Khan H., Watt S.R., Watt M.-A.V., Lu Y., Fang X., Tsutsui S., Siddik Z.H., Bast R.C. Jr, Mills G.B. Overexpression of Edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin. Cancer Res. 5:1999;4308-4318.
20. Fang X., Schummer M., Mao M., Yu S., Tabassam F.H., Swaby R., Hasegawa Y., Tanyi J.L., LaPushin R., Eder A., Jaffe R., Erickson J., Mills G.B. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim. Biophys. Acta. 1582:2002;257-264.
21. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. 1979;World Health Organization, Geneva, Switzerland.
22. Silverberg S.G. Histopathologic grading of ovarian carcinoma: a review and proposal. Int. J. Gynecol. Pathol. 19:2000;7-15.
23. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
24. Zhang Q., Peyruchaud O., French K.J., Magnusson M.K., Mosher D.F. Sphingosine 1-phosphate stimulates fibronectin matrix assembly through a rho-dependent signal pathway. Blood. 93:1999;2984-2990.
25. Fujimoto J., Sakaguchi H., Hirose R., Ichigo S., Tamaya T. Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer. 83:1998;2528-2533.
26. Tartour E., Fossiez F., Joyeux I., Galinha A., Gey A., Claret E., Sastre-Garau X., Couturier J., Mosseri V., Vives V., Banchereau J., Fridman W.H., Wijdenes J., Lebecque S., Sautes-Fridman C. Interleukin 17, a T-cell-derived cytokine promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 59:1999;3698-3704.
27. Barbieri F., Cagnoli M., Ragni N., Foglia G., Bruzzo C., Pedulla F., Alama A. Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. Clin. Cancer Res. 5:1999;1837-1842.
28. A1/vzg-1/Gpcr26. Genomics. 51:1998;364-378.
29. A3/EDG-7 in neuronal cell lines using a retrovirus expression system. Mol. Pharmacol. 58:2000;895-902.
30. Contos J.J.A., Chun J. Genomic characterization of the lysophosphatidic acid receptor gene, lpA2/Edg4, and identification of a frameshift mutation in a previously characterized cDNA. Genomics. 64:2000;155-169.
31. Sonoda G., Palazzo J., du Manoir S., Godwin A.K., Feder M., Yakushiji M., Testa J.R. Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes Cancer. 20:1997;320-328.
32. Boyd J.A., Hamilton T.C., Berchuck A. Oncogenes and tumor-suppressor genes. Hoskins W.J., Perez C.A., Young R.C. Gynecologic Oncology: Principles and Practice. third ed. 2000;103-128 Lippincott Williams and Wilkins, Philadelphia, PA.
33. Duyndam M.C.A., Hulscher T.M., Fontijn D., Pinedo H.M., Boven E. Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1α protein by the oxidative stressor arsenite. J. Biol. Chem. 51:2001;48066-48076.
34. Goetzl E.J., Lee H., Azumi T., Stossel T.P., Karliner J.S. Gelsolin (GS) binding of lysophosphatidic acid (LPA) and enhancement of presentation of LPA to rat cardiac myocytes (RCMs). FASEB J. 13A:1999;1423.
35. Folkman J., Klagsbrun M. Angiogenic factors. Science. 235:1987;442-447.
36. Fidler I.J., Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 79:1994;185-188.
37. Xu L., Xie K., Mukaida N., Matsushima K., Filder I.J. Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells. Cancer Res. 59:1999;5822-5829.
38. Semenza G.L., Nejfelt M.K., Chi S.M., Antonarakis S.E. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc. Natl. Acad. Sci. USA. 88:1991;5680-5684.
39. Semenza G.L., Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell Biol. 12:1992;5447-5454.
40. Kvietikova I., Wenger R.H., Marti H.H., Gassmann M. The transcription factors ATE-1 and CREB-1 bind constitutively to the hypoxia-inducible factor-1 (HIF-1) DNA recognition site. Nucleic Acids Res. 23:1995;4542-4550.
41. Lu J., Xiao Y.-J., Baudhuin L.M., Hong G., Xu Y. Role of ether-linked lysophosphatidic acids in ovarian cancer cells. J. Lipid Res. 43:2002;463-476.
42. Shen Z., Wu M., Elson P., Kennedy A.W., Belinson J., Casey G., Xu Y. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases. Gynecol. Oncol. 83:2001;25-30.
43. Bandoh K., Aoki J., Taira A., Tsujimoto M., Arai H., Inoue K. Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species: structure-activity relationship of cloned LPA receptors. FEBS Lett. 478:2000;159-165.
44. 2. Clin. Cancer Res. 6:2000;2482-2491.